FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia

Kasidy K. Dobish, Karli J. Wittorf, Samantha A. Swenson, Dalton C. Bean, Catherine M. Gavile, Nicholas T. Woods, Gargi Ghosal, R. Katherine Hyde, Shannon M. Buckley

Research output: Contribution to journalArticlepeer-review


Acute myeloid leukemia (AML) is a heterogeneous disease characterized by clonal expansion of myeloid blasts in the bone marrow (BM). Despite advances in therapy, the prognosis for AML patients remains poor, and there is a need to identify novel molecular pathways regulating tumor cell survival and proliferation. F-box ubiquitin E3 ligase, FBXO21, has low expression in AML, but expression correlates with survival in AML patients and patients with higher expression have poorer outcomes. Silencing FBXO21 in human-derived AML cell lines and primary patient samples leads to differentiation, inhibition of tumor progression, and sensitization to chemotherapy agents. Additionally, knockdown of FBXO21 leads to up-regulation of cytokine signaling pathways. Through a mass spectrometry-based proteomic analysis of FBXO21 in AML, we identified that FBXO21 ubiquitylates p85α, a regulatory subunit of the phosphoinositide 3-kinase (PI3K) pathway, for degradation resulting in decreased PI3K signaling, dimerization of free p85α and ERK activation. These findings reveal the ubiquitin E3 ligase, FBXO21, plays a critical role in regulating AML pathogenesis, specifically through alterations in PI3K via regulation of p85α protein stability.

Original languageEnglish (US)
Pages (from-to)2197-2208
Number of pages12
Issue number11
StatePublished - Nov 2023

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this